Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized, Blinded Trial of Mesna to Prevent Doxorubicin-induced Plasma Protein Oxidation and TNF-α Release

NCT01205503 is registered in ClinicalTrials.gov with Mara Chambers as lead sponsor.

NCT NCT01205503
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01205503 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized, Blinded Trial of Mesna to Prevent Doxorubicin-induced Plasma Protein Oxidation and TNF-α Release
Lead sponsor
Mara Chambers
Phase
Phase 2
Overall status
Completed
Start date
September 30, 2010
Completion date
April 30, 2015
Enrollment
32 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, non-hodgkin's lymphoma